Search:
Friday, Feb-21 2020 09:13 WIB
  • AGRI 1,294.230 1.080 (0.084%)
  • BASIC-IND 875.550 -7.450 (-0.844%)
  • BISNIS-27 536.480 -1.510 (-0.281%)
  • COMPOSITE 5,933.970 -8.520 (-0.143%)
  • CONSUMER 1,931.400 -6.130 (-0.316%)
  • DBX 1,035.390 5.410 (0.525%)
  • FINANCE 1,347.500 -1.690 (-0.125%)
  • I-GRADE 173.350 -0.320 (-0.184%)
  • IDX30 527.550 -1.790 (-0.338%)
  • IDX80 135.110 -0.510 (-0.376%)
  • IDXBUMN20 373.530 -2.000 (-0.533%)
  • IDXG30 138.580 -0.450 (-0.324%)
  • IDXHIDIV20 482.020 -1.630 (-0.337%)
  • IDXSMC-COM 236.830 0.130 (0.055%)
  • IDXSMC-LIQ 284.580 -1.090 (-0.382%)
  • IDXV30 128.530 -0.480 (-0.372%)
  • INFOBANK15 1,034.340 -1.550 (-0.150%)
  • INFRASTRUC 1,021.110 3.630 (0.357%)
  • Investor33 450.730 -1.160 (-0.257%)
  • ISSI 171.220 -0.270 (-0.157%)
  • JII 631.140 -2.640 (-0.417%)
  • JII70 211.370 -0.780 (-0.368%)
  • KOMPAS100 1,206.770 -3.460 (-0.286%)
  • LQ45 965.430 -3.110 (-0.321%)
  • MANUFACTUR 1,342.130 -6.530 (-0.484%)
  • MBX 1,660.880 -3.900 (-0.234%)
  • MINING 1,454.850 -0.050 (-0.003%)
  • MISC-IND 1,098.810 -3.190 (-0.289%)
  • MNC36 336.140 -0.890 (-0.264%)
  • PEFINDO25 305.770 -0.180 (-0.059%)
  • PROPERTY 455.710 -0.170 (-0.037%)
  • SMinfra18 296.500 -1.160 (-0.390%)
  • SRI-KEHATI 385.280 -0.720 (-0.187%)
  • TOTAL_MARKET 5,934.000 -8.490 (-0.143%)
  • TRADE 705.620 1.420 (0.202%)
  • © 2010 IMQ - LKBN ANTARA
  • AALI 11,125 -25 (-0.22%)
  • ABBA 64 0 (0.00%)
  • ACES 1,565 5 (0.32%)
  • ADHI 965 -5 (-0.52%)
  • ADMF 10,200 200 (2.00%)
  • ADMG 131 0 (0.00%)
  • ADRO 1,345 -5 (-0.37%)
  • AGRO 152 1 (0.66%)
  • AKRA 3,050 -10 (-0.33%)
  • AMAR 310 2 (0.65%)
  • ANDI 50 0 (0.00%)
  • ANTM 710 0 (0.00%)
  • APLN 155 -1 (-0.64%)
  • ARKA 1,965 20 (1.03%)
  • ASGR 930 0 (0.00%)
  • ASII 6,250 -25 (-0.40%)
  • ASPI 310 6 (1.97%)
  • ASPI-W 22 0 (0.00%)
  • ASRI 177 0 (0.00%)
  • ASSA 555 5 (0.91%)
  • AUTO 1,160 0 (0.00%)
  • AYLS 169 -35 (-17.16%)
  • AYLS-W 17 0 (0.00%)
  • BABP-W3 32 -3 (-8.57%)
  • BAPA 52 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • BBCA 33,150 175 (0.53%)
  • BBKP 208 -6 (-2.80%)
  • BBNI 7,850 -75 (-0.95%)
  • BBRI 4,540 -20 (-0.44%)
  • BBTN 1,915 -5 (-0.26%)
  • BDMN 3,720 -20 (-0.53%)
  • BEEF-W 40 2 (5.26%)
  • BEST 166 -1 (-0.60%)
  • BFIN 498 0 (0.00%)
  • BGTG 51 1 (2.00%)
  • BHIT 64 1 (1.59%)
  • BIRD 2,390 0 (0.00%)
  • BJBR 1,010 -10 (-0.98%)
  • BJTM 635 0 (0.00%)
  • BKSL 53 1 (1.92%)
  • BKSL-W 11 2 (22.22%)
  • BLUE 540 5 (0.93%)
  • BMRI 7,925 -75 (-0.94%)
  • BMTR 344 0 (0.00%)
  • BNGA 870 0 (0.00%)
  • BNLI 1,235 5 (0.41%)
  • BOSS 105 -3 (-2.78%)
  • BRIS 304 0 (0.00%)
  • BRMS 50 0 (0.00%)
  • BRPT 1,190 -30 (-2.46%) © 2010 IMQ - LKBN ANTARA
  • BSDE 1,150 10 (0.88%)
  • BTPS 4,350 0 (0.00%)
  • BULL 162 2 (1.25%)
  • BUMI 51 1 (2.00%)
  • BVIC 66 0 (0.00%)
  • BWPT 113 1 (0.89%)
  • CAKK 52 0 (0.00%)
  • CARS 85 -1 (-1.16%)
  • CCSI 252 2 (0.80%)
  • CENT 70 2 (2.94%)
  • CINT 288 14 (5.11%)
  • CLAY 2,820 0 (0.00%)
  • CLEO 478 -2 (-0.42%)
  • COCO 865 -65 (-6.99%)
  • CPIN 6,750 -100 (-1.46%)
  • CSIS 67 1 (1.52%)
  • CSRA 590 -5 (-0.84%)
  • CTRA 960 -15 (-1.54%)
  • DADA 160 -2 (-1.23%)
  • DADA-W 14 2 (16.67%)
  • DEAL 138 -2 (-1.43%)
  • DFAM 390 -2 (-0.51%)
  • DILD 278 2 (0.72%)
  • DKFT 119 -2 (-1.65%)
  • DMAS 282 -6 (-2.08%) © 2010 IMQ - LKBN ANTARA
  • DMMX 180 0 (0.00%)
  • DMND 930 -20 (-2.11%)
  • DOID 220 -4 (-1.79%)
  • DWGL 278 0 (0.00%)
  • DYAN 63 -1 (-1.56%)
  • EAST 86 0 (0.00%)
  • EAST-W 12 -1 (-7.69%)
  • EKAD 1,050 -5 (-0.47%)
  • ELSA 262 0 (0.00%)
  • ENRG 50 0 (0.00%)
  • ERAA 1,855 75 (4.21%)
  • ESIP-W 15 0 (0.00%)
  • ESSA 234 -4 (-1.68%)
  • EXCL 2,640 -40 (-1.49%)
  • FILM 193 -7 (-3.50%)
  • FIRE 136 2 (1.49%)
  • FOOD 93 0 (0.00%)
  • FPNI 84 -1 (-1.18%)
  • FREN 106 2 (1.92%)
  • GDST 74 1 (1.37%)
  • GGRM 55,400 -175 (-0.31%)
  • GGRP 478 56 (13.27%)
  • GIAA 334 0 (0.00%)
  • GJTL 486 4 (0.83%)
  • GLOB 348 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • GMFI 98 1 (1.03%)
  • GOOD 1,325 0 (0.00%)
  • HEAL 3,390 0 (0.00%)
  • HELI-W 13 1 (8.33%)
  • HEXA 3,200 0 (0.00%)
  • HKMU 141 -3 (-2.08%)
  • HMSP 1,940 -5 (-0.26%)
  • HOKI 1,000 0 (0.00%)
  • HRME 950 0 (0.00%)
  • HRUM 1,215 0 (0.00%)
  • IBFN-W 21 4 (23.53%)
  • ICBP 11,250 25 (0.22%)
  • IFII 169 7 (4.32%)
  • IKAN 206 -4 (-1.90%)
  • IMAS 855 0 (0.00%)
  • INAF 685 -5 (-0.72%)
  • INAI 412 -2 (-0.48%)
  • INCO 3,140 20 (0.64%)
  • INDF 7,250 -50 (-0.68%)
  • INDO 107 -5 (-4.46%)
  • INDO-W 30 -10 (-25.00%)
  • INDY 920 -15 (-1.60%)
  • INKP 6,600 -25 (-0.38%)
  • INPS 3,910 10 (0.26%)
  • INTD 284 48 (20.34%) © 2010 IMQ - LKBN ANTARA
  • INTP 16,925 -375 (-2.17%)
  • IPOL 70 0 (0.00%)
  • IRRA 750 0 (0.00%)
  • ISAT 2,270 -30 (-1.30%)
  • ISSP 177 0 (0.00%)
  • ITIC 2,030 -20 (-0.98%)
  • ITMG 10,775 -150 (-1.37%)
  • JPFA 1,565 -25 (-1.57%)
  • JRPT 488 -2 (-0.41%)
  • JSKY 113 1 (0.89%)
  • JSMR 5,025 -25 (-0.50%)
  • JTPE 985 0 (0.00%)
  • KAEF 810 -10 (-1.22%)
  • KARW 52 0 (0.00%)
  • KAYU 64 -1 (-1.54%)
  • KBLI 462 -2 (-0.43%)
  • KEEN 388 -8 (-2.02%)
  • KEJU 835 0 (0.00%)
  • KIJA 292 0 (0.00%)
  • KINO 3,120 0 (0.00%)
  • KLBF 1,395 -25 (-1.76%)
  • KOBX 112 -5 (-4.27%)
  • KOTA 740 15 (2.07%)
  • KPAS 53 1 (1.92%)
  • KPIG 125 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • KRAS 270 0 (0.00%)
  • KREN 470 0 (0.00%)
  • LAND 950 90 (10.47%)
  • LCKM 340 8 (2.41%)
  • LINK 3,560 -10 (-0.28%)
  • LMAS 94 -1 (-1.05%)
  • LPCK 825 0 (0.00%)
  • LPKR 232 0 (0.00%)
  • LPPF 3,630 80 (2.25%)
  • LSIP 1,160 10 (0.87%)
  • LUCK 432 -4 (-0.92%)
  • MAIN 875 5 (0.57%)
  • MAMI-W 12 0 (0.00%)
  • MAPI 850 5 (0.59%)
  • MARK 478 0 (0.00%)
  • MBSS 432 0 (0.00%)
  • MDKA 1,320 20 (1.54%)
  • MEDC 720 5 (0.70%)
  • MEDC-W 140 -5 (-3.45%)
  • MERK 2,200 -30 (-1.35%)
  • META 150 0 (0.00%)
  • MGRO 825 0 (0.00%)
  • MIKA 2,590 0 (0.00%)
  • MINA 84 17 (25.37%)
  • MKNT 50 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • MLIA 605 5 (0.83%)
  • MMLP 174 0 (0.00%)
  • MNCN 1,455 -20 (-1.36%)
  • MPMX 640 0 (0.00%)
  • MPPA 119 2 (1.71%)
  • MRAT 145 0 (0.00%)
  • MYOR 1,975 -10 (-0.50%)
  • NATO 1,130 -5 (-0.44%)
  • NIKL 484 2 (0.41%)
  • NISP 845 -10 (-1.17%)
  • NUSA-W 4 1 (33.33%)
  • OKAS 105 0 (0.00%)
  • PAMG 161 1 (0.62%)
  • PANR 244 0 (0.00%)
  • PANS 1,295 90 (7.47%)
  • PBID 990 5 (0.51%)
  • PBRX 382 -2 (-0.52%)
  • PGAS 1,545 -10 (-0.64%)
  • PGJO 84 -9 (-9.68%)
  • PICO 745 -5 (-0.67%)
  • PMJS 124 -1 (-0.80%)
  • PNBN 1,230 0 (0.00%)
  • PNLF 278 -2 (-0.71%)
  • POLL 11,625 0 (0.00%)
  • POLY 51 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • POSA-W 4 0 (0.00%)
  • PPRE 198 0 (0.00%)
  • PPRO 52 0 (0.00%)
  • PSAB 256 6 (2.40%)
  • PTBA 2,450 -40 (-1.61%)
  • PTPP 1,460 -15 (-1.02%)
  • PTPW 875 0 (0.00%)
  • PTRO 1,495 -5 (-0.33%)
  • PURA 206 0 (0.00%)
  • PURA-W 14 0 (0.00%)
  • PURE 127 2 (1.60%)
  • PURE-W 29 -1 (-3.33%)
  • PWON 580 0 (0.00%)
  • PZZA 1,010 0 (0.00%)
  • RAJA 126 2 (1.61%)
  • RALS 990 -5 (-0.50%)
  • REAL 113 1 (0.89%)
  • REAL-W 13 0 (0.00%)
  • RISE 468 0 (0.00%)
  • RODA 60 2 (3.45%)
  • SATU 57 4 (7.55%)
  • SCMA 1,325 -5 (-0.38%)
  • SDPC 99 2 (2.06%)
  • SHIP 740 -5 (-0.67%)
  • SIDO 1,305 5 (0.38%) © 2010 IMQ - LKBN ANTARA
  • SILO 6,850 0 (0.00%)
  • SIMP 354 -2 (-0.56%)
  • SLIS 4,750 0 (0.00%)
  • SMBR 310 -2 (-0.64%)
  • SMDR 200 0 (0.00%)
  • SMGR 11,700 -75 (-0.64%)
  • SMRA 890 -15 (-1.66%)
  • SMSM 1,435 -5 (-0.35%)
  • SOCI 137 0 (0.00%)
  • SQMI 260 8 (3.17%)
  • SRAJ 236 16 (7.27%)
  • SRIL 226 -2 (-0.88%)
  • SRSN 61 0 (0.00%)
  • SSIA 680 -5 (-0.73%)
  • SSMS 790 -10 (-1.25%)
  • STTP 9,225 1,525 (19.81%)
  • SWAT 88 0 (0.00%)
  • TAMA 424 -2 (-0.47%)
  • TAMA-W 19 0 (0.00%)
  • TAMU 163 -1 (-0.61%)
  • TBIG 1,185 5 (0.42%)
  • TBLA 755 10 (1.34%)
  • TCPI 7,125 0 (0.00%)
  • TELE 179 2 (1.13%)
  • TGRA 100 -1 (-0.99%) © 2010 IMQ - LKBN ANTARA
  • TINS 700 0 (0.00%)
  • TKIM 8,075 -150 (-1.82%)
  • TLKM 3,660 30 (0.83%)
  • TMAS 91 2 (2.25%)
  • TOPS 50 0 (0.00%)
  • TOTL 410 2 (0.49%)
  • TOWR 880 0 (0.00%)
  • TPIA 9,075 25 (0.28%)
  • TRIN 234 -2 (-0.85%)
  • UCID 1,610 10 (0.62%)
  • ULTJ 1,620 0 (0.00%)
  • UNSP 90 1 (1.12%)
  • UNTR 18,550 125 (0.68%)
  • UNVR 7,575 -75 (-0.98%)
  • VINS 112 2 (1.82%)
  • WEGE 288 2 (0.70%)
  • WEHA 147 0 (0.00%)
  • WIKA 2,040 0 (0.00%)
  • WOMF 294 -4 (-1.34%)
  • WOOD 476 -4 (-0.83%)
  • WOWS 106 2 (1.92%)
  • WSBP 230 0 (0.00%)
  • WSKT 1,205 -10 (-0.82%)
  • WTON 388 -2 (-0.51%)
  • XIIT 545 -1 (-0.18%) © 2010 IMQ - LKBN ANTARA
  • ZINC 350 0 (0.00%)
  • ZONE 488 0 (0.00%)
Ferring’s Propess® is the first pharmacological treatment for cervical ripening to be approved in Japan for over 20 years
Published: 23 Jan 2020 15:30 WIB


IMQ, Jakarta —  • Ferring announces that the Minister of Health, Labour and Welfare (MHLW) in Japan has approved Propess® (dinoprostone) for the initiation of cervical ripening1
• Propess, developed in Scotland, UK, and marketed in over 60 countries, was approved following close collaboration with the patient community in Japan
• This approval provides women in Japan with greater choice and is part of Ferring’s commitment to advancing Reproductive Medicine and Maternal Health worldwide

SAINT-PREX, Switzerland--(Antara/BUSINESS WIRE)-- Ferring Pharmaceuticals today announced that Propess® (dinoprostone) has been approved by the Minister of Health, Labour and Welfare (MHLW) in Japan for initiation of cervical ripening in patients at term (from 37 completed weeks of gestation).1 This is the first time in over 20 years that a pharmacological therapy for cervical ripening has been approved in the country.2

Around 10 per cent of births globally require induction of labour, which may be required if the health of the mother or baby is at risk.3,4 Cervical ripening is carried out prior to induction to prepare the cervix for birth. This approval offers women requiring an induction in Japan greater choice of alternatives to mechanical methods of cervical ripening.

“The approval of Propess in Japan is a big step forward in offering women more choice when it comes to cervical ripening,” said Per Falk, President and Chief Science Officer, Ferring Pharmaceuticals. “There is a lack of research and development of treatment options for women who are pregnant or giving birth, which is why it is important for Ferring to continue to invest and advance the field of Reproductive Medicine and Maternal Health and continue with our purpose of building families worldwide.”

The announcement today follows a close collaboration between Ferring Pharmaceuticals and a local patient advocacy group to ensure the needs and safety of women in labour are addressed in Japan.

“For women giving birth, mechanical methods may not always be the right option and it is important that a woman’s safety and comfort is paramount,” said Mikiya Kitamura, Vice President, Ferring Japan R&D. “Ensuring that a treatment is safe and effective is a priority for us, and we are pleased to have been able to work together with our local patient advocacy group on this significant milestone.”

Propess is currently marketed in over 60 countries and was developed in the 1980s in Scotland where it continues to be manufactured. As leaders in Reproductive Medicine and Maternal Health, this approval demonstrates Ferring’s continued commitment to helping people around the world to build healthy families.

About Propess5

Propess is a vaginal delivery system containing the active substance dinoprostone 10 mg used for the initiation of cervical ripening in women at term (from 37 completed weeks of gestation). The dinoprostone softens and opens the part of the birth canal known as the cervix, to start the process of labour.

About labour6

Labour is initiated or induced by obstetricians in situations where it is considered safer, for the mother or the unborn child, to be delivered. This could be due to pre-eclampsia (sudden, severe rise in blood pressure and kidney impairment), poor growth in the baby, unexplained bleeding in the last phase of pregnancy or a prolonged pregnancy (the most common reason). The success of induction of labour is related to the condition of the cervix prior to the induction. If during examination of the cervix length, positioning and softening, it is deemed unfavourable, then cervical ripening will be initiated.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build healthy families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

References

1 Minister of Health, Labour and Welfare (MHLW). Approval of Propess (dinoprostone). January 2020. Japan New Drug Application (NDA) approval document.
2 Ferring Pharmaceuticals. Data on file. January 2020.
3 World Health Organization. WHO Recommendations for Induction of Labour. Geneva: World Health Organization; 2011. Available at: https://www.who.int/reproductivehealth/publications/maternal_perinatal_health/9789241501156/en/ Last accessed: January 2020.
4 The American College of Obstetricians and Gynecologists. Frequently asked questions: Labor delivery and postpartum care. Available at: https://www.acog.org/Patients/FAQs/Labor-Induction?IsMobileSet=false Last accessed: January 2020.
5 Propess summary of product characteristics (SmPC). Available at: https://www.medicines.org.uk/emc/product/135/smpc. Last accessed: January 2020.
6 World Health Organization. Managing complications in pregnancy and childbirth: a guide for midwives and doctors – 2nd ed. Geneva: World Health Organization; 2017. Available at: https://www.who.int/maternal_child_adolescent/documents/managing-complications-pregnancy-childbirth/en/. Last accessed: January 2020

View source version on businesswire.com: https://www.businesswire.com/news/home/20200122005902/en/

Contacts
Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com

Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com

Source: Ferring Pharmaceuticals
Author: Business Wire
-
POPULAR NEWS